Semax Nasal Spray
Semax nasal spray is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH 4-10) developed for preclinical investigation into neuroprotection, brain-derived neurotrophic factor (BDNF) expression, and central nervous system signaling. Formulated specifically for mucosal and intranasal administration models, this research compound allows investigators to evaluate central peptide transport without invasive parenteral delivery.
Quick answer
Semax nasal spray is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH 4-10) developed for preclinical investigation into neuroprotection, brain-derived neurotrophic factor (BDNF) expression, and central nervous system signaling. Formulated specifically for mucosal and intranasal administration models, this research compound allows investigators to evaluate central peptide transport without invasive parenteral delivery.
Key takeaways
- [Semax](/research-peptides/semax) is a synthetic heptapeptide derivative with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro.
- In preclinical literature, [Semax](/research-peptides/semax) has demonstrated a primary mechanism centered on the rapid modulation of neurotrophic factors, most notably Brain-Derived Neurotrophic Factor (BDNF) and its primary receptor, tropomyosin receptor kinase B (TrkB).
- When designing neurobiological research protocols, investigators frequently compare [Semax](/research-peptides/semax) against related central neuropeptides to evaluate divergent signaling pathways and physiological targets.
- Intranasal administration represents a key delivery vector in non-human primate and rodent studies assessing direct mucosa-to-brain peptide transport.
Chemical Structure and Molecular Profile of Semax
Semax is a synthetic heptapeptide derivative with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was engineered by modifying the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10) through the addition of a C-terminal Pro-Gly-Pro tripeptide motif. This chemical alteration significantly enhances the peptide's resistance to enzymatic degradation by endogenous peptidases, thereby prolonging its half-life during in vitro assays and animal model evaluations.
The incorporation of the Pro-Gly-Pro sequence stabilizes the peptide structure against rapid proteolytic cleavage without retaining systemic endocrine or glucocorticoid-stimulating activity typical of full-length ACTH. Researchers investigating peptide dynamics often cross-reference the chemical structure of Semax with other modified fragments across our catalog of research peptides to understand how terminal capping influences metabolic half-life in laboratory models. Additional foundational data can be accessed via our dedicated Semax research monograph.
Preclinical Mechanisms of Action: BDNF Upregulation and Signal Transduction
In preclinical literature, Semax has demonstrated a primary mechanism centered on the rapid modulation of neurotrophic factors, most notably Brain-Derived Neurotrophic Factor (BDNF) and its primary receptor, tropomyosin receptor kinase B (TrkB). Quantitative polymerase chain reaction (qPCR) and Western blot analyses in rodent models indicate that administration of Semax leads to a marked upregulation of BDNF mRNA transcripts within the hippocampus and basal forebrain regions.
Furthermore, preclinical studies suggest that Semax influences central monoaminergic transmission. Laboratory models demonstrate increased turnover of dopamine and serotonin within the striatum and prefrontal cortex. Rather than acting as a direct receptor agonist, Semax appears to exert a neuromodulatory effect, sensitizing receptor complexes to endogenous ligand interactions. These biochemical cascades are actively studied in animal assays to determine how peptide exposure affects synaptic plasticity, long-term potentiation (LTP), and neurovascular integrity under physiological and ischemic stress conditions.
Comparative Analysis: Semax vs. Related Neuropeptide Compounds
When designing neurobiological research protocols, investigators frequently compare Semax against related central neuropeptides to evaluate divergent signaling pathways and physiological targets. The primary compounds evaluated alongside Semax include Selank, an anxiolytic heptapeptide derived from tuftsin; Noopept, a synthetic dipeptide derivative evaluated for cognitive and neuroprotective activity; and BPC-157, a tissue-repair peptide studied for pleiotropic cytoprotection.
While Semax demonstrates a pronounced preference for BDNF gene expression, TrkB signaling, and dopaminergic activity, Selank operates primarily through GABAergic pathways and interleukin-6 (IL-6) immune modulation. Noopept differs fundamentally in structural classification, functioning as a proline-containing dipeptide that stimulates nerve growth factor (NGF) along with BDNF. In contrast, BPC-157 acts largely on angiogenic and mucosal stabilization cascades. Comparing these molecules within controlled in vitro models enables researchers to map distinct receptor affinities and downstream cellular responses.
Intranasal Delivery Dynamics and Mucosa-to-Brain Transport
Intranasal administration represents a key delivery vector in non-human primate and rodent studies assessing direct mucosa-to-brain peptide transport. The nasal cavity offers a direct, non-invasive anatomical pathway to the central nervous system via the olfactory and trigeminal nerve pathways, effectively bypassing the tight junctions of the systemic blood-brain barrier (BBB).
Preclinical radiolabeling experiments demonstrate that intranasally delivered Semax rapidly accumulates in olfactory bulb tissues, the anterior hypothalamus, and cerebral cortex structures within minutes of application. Utilizing a dedicated liquid vehicle such as the Semax research peptide solution allows research teams to establish standardized volumetric dosing per spray actuation, ensuring reproducible concentration delivery across experimental trial groups.
In Vitro Findings and Ischemic Stress Research Models
A major subset of Semax literature investigates its cytoprotective properties in cellular hypoxia and rodent focal ischemia models. In vitro assays using primary neuronal cultures subjected to oxygen-glucose deprivation (OGD) demonstrate that Semax pretreatment preserves mitochondrial membrane potential and reduces markers of apoptotic cell death, such as caspase-3 activation.
In vivo rodent models of middle cerebral artery occlusion (MCAO) show that Semax administration reduces stroke infarct volume and downregulates pro-inflammatory cytokine expression, including TNF-alpha and IL-1 beta. Simultaneously, researchers observe an increase in vascular endothelial growth factor (VEGF) expression, suggesting a potential pro-angiogenic effect in ischemic tissue margins. Detailed documentation regarding these cellular responses is compiled within our central research database.
Reconstitution, Handling, and Buffer Compatibility
To ensure experimental validity, high-purity Semax must be handled in strict accordance with analytical standards. Reconstitution of lyophilized Semax powder should be performed using sterile, laboratory-grade solvents such as 0.9% sodium chloride (bacteriostatic or standard sterile saline) or phosphate-buffered saline (PBS) maintained at an optimal pH range of 6.0 to 7.4.
When preparing intranasal research formulations, physical agitations such as violent vortexing must be avoided to prevent peptide shear stress and denaturation. Gentle swirl mixing is recommended. Once dissolved into liquid form, the peptide solution should be stored in sterile, amber glass or high-density polyethylene (HDPE) spray containers to prevent photodegradation and adsorption to container walls.
Storage Conditions and Temperature Stability
Lyophilized Semax peptide exhibits high chemical stability when maintained in a desiccated state at -20°C or -80°C for long-term storage. Under these ultra-low temperature conditions, peptide degradation is minimized, preserving purity levels above 98% for extended periods.
Following reconstitution into an aqueous nasal spray formulation, the liquid solution should be refrigerated at 2°C to 8°C. Researchers should avoid repeated freeze-thaw cycles of reconstituted liquid solutions, as ice crystal formation can rupture peptide bonds and accelerate degradation. Reconstituted aqueous samples kept at refrigerated temperatures typically maintain functional stability for short-term experimental windows (2 to 4 weeks), provided aseptic handling is strictly observed.
Analytical Quality Control: RP-HPLC and Mass Spectrometry Verification
Precision in laboratory research requires verified chemical identity and absolute purity. PX1 Research subjects every production lot of Semax to rigorous two-tier analytical verification consisting of Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
RP-HPLC analysis establishes peptide purity by separating target molecules from synthesis byproducts, truncated sequences, and residual protecting groups, ensuring a minimum purity threshold of >98.0%. ESI-MS verifies the exact molecular weight of the heptapeptide sequence, confirming the correct mass-to-charge ratio (m/z) corresponding to the theoretical mass of Semax (810.9 g/mol). Every product batch is delivered with a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory.
Endotoxin Testing and Environmental Controls
Bacterial endotoxins, specifically lipopolysaccharides (LPS) derived from Gram-negative outer membranes, pose a significant confounding variable in cell culture and animal model experiments. Exposure to trace endotoxins can trigger non-specific inflammatory signaling cascades, invalidating scientific observations related to cytokine dynamics or neuroprotection.
PX1 Research conducts mandatory Limulus Amebocyte Lysate (LAL) testing on all Semax batches. Our strict quality specifications require endotoxin levels to remain well below standardized thresholds (<0.05 EU/mg). Products are synthesized within cGMP-compliant facilities using closed-system automation to prevent microbial contamination and environmental degradation.
PX1 Research Supply Chain, Traceability, and Shipping Standards
All PX1 Research compounds are manufactured in the United States under strict quality management frameworks. We maintain full lot-traceability from raw amino acid precursor sourcing through final lyophilization and packaging. This end-to-end oversight ensures complete consistency between experimental runs across different laboratory facilities.
To protect peptide integrity during transit, orders placed with PX1 Research are processed with same-day shipping, Monday through Friday, departing directly from our primary distribution hubs in California and Arizona. Facilities requiring ongoing batch quantities or custom bulk formulations for long-term studies can establish dedicated fulfillment protocols through our wholesale lab account options.
Frequently Asked Questions
What is semax nasal spray used for in laboratory research?
Semax nasal spray is used in preclinical laboratory settings to study neuroprotection, BDNF gene expression, central peptidergic transport, and neurotransmitter modulation without requiring invasive parenteral injections in animal models.
What is the molecular sequence of Semax?
Semax is a synthetic heptapeptide with the molecular sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analog of the N-terminal fragment of ACTH(4-10) stabilized with a C-terminal tripeptide.
How does semax nasal spray differ from injectable Semax formulations?
Semax nasal spray is formulated in a liquid vehicle calibrated for intranasal mucosal administration, allowing researchers to study olfactory-to-brain peptide uptake, whereas lyophilized injectable forms require manual reconstitution for systemic or parenteral administration models.
What storage temperature is required for semax nasal spray?
Lyophilized Semax powder should be stored at -20°C for long-term stability. Once reconstituted into a nasal spray solution, it should be kept refrigerated at 2°C to 8°C and protected from direct light exposure.
How do researchers verify the purity of semax nasal spray?
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity levels >98%, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to validate molecular weight.
What are the endotoxin limits for PX1 Research Semax?
PX1 Research enforces a strict endotoxin threshold of <0.05 EU/mg, verified via Limulus Amebocyte Lysate (LAL) testing to ensure compounds do not induce non-specific inflammatory responses in research assays.
Which central pathways are targeted by Semax in preclinical literature?
Preclinical studies show Semax targets BDNF/TrkB signaling, upregulates hippocampal nerve growth factors, and modulates dopaminergic and serotonergic turnover in central nervous system tissues.
How does Semax compare to Selank in experimental studies?
While Semax primarily modulates BDNF, dopaminergic signaling, and ischemic cellular responses, Selank operates predominantly through GABAergic systems and cytokine regulation. Both are proline-stabilized heptapeptides used in neurobiological research.
What solvent is recommended for reconstituting Semax peptide?
Reconstitution is typically performed using sterile 0.9% sodium chloride saline or sterile phosphate-buffered saline (PBS) maintained at neutral pH (6.5–7.4).
Where does PX1 Research manufacture and ship its Semax nasal spray?
PX1 Research compounds are manufactured in USA-based cGMP-compliant facilities and shipped same-day (Monday through Friday) from distribution centers in California and Arizona.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.